Women-only constipation treatment now licensed in men

Prescribers can now consider the 5HT4 agonist prucalopride (Resolor) as an option for men with chronic constipation resistant to laxative treatment.

Prucalopride (Resolor) stimulates intestinal motility.
Prucalopride (Resolor) stimulates intestinal motility.

Prucalopride was originally approved for use only in women, as almost 90% of participants in the pivotal trials of the drug were female - reflecting the smaller number of men who seek medical care for chronic constipation.

Now, a randomised, placebo-controlled, double-blind study has confirmed the safety and efficacy of the drug in men with chronic constipation.

Comparable efficacy in men and women

Investigators enrolled 374 men with chronic constipation, defined as two or fewer spontaneous complete bowel movements (SCBMs) per week, as well as one or more of the following for at least 6 months:

  • at least 25% of stools being very hard or hard
  • sensation of incomplete evacuation following at least 25% of defaecations
  • straining at defaecation for at least 25% of the time.

Prucalopride was significantly more effective than placebo at increasing the number of bowel movements, with 37.9% of patients in the prucalopride group and 17.7% of those in the placebo group achieving a mean of 3 or more SCBMs per week over the 12-week treatment period (p<0.0001).

Quality of life benefit

Prucalopride also improved health-related quality of life. The mean change from baseline in Patient Assessment of ConstipationQuality of Life (PAC-QOL) questionnaire score was significantly greater in the men treated with prucalopride than in those who received placebo (0.79 vs 0.59, p=0.0158).

The proportion of patients with an improvement of at least 1 point in PAC-QOL satisfaction subscale score was 52.7% in the prucalopride group compared with 38.8% in the placebo group (p=0.0035).

Well tolerated

Prucalopride was well tolerated in men, with no significant difference in the rate of treatment-emergent adverse events compared with placebo.

The most common treatment-emergent adverse events seen with prucalopride were diarrhoea, nausea, abdominal pain and headache.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Avoid routinely offering antidepressants for 'less severe' depression, says NICE in draft guidance
Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...